- Patients
- Clinical Research
- Clinical trials
- FURMO-002
Lung Cancer
FURMO-002
A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumour activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFRor her2 mutations.
Trial overview
Medical Oncology
Lung cancer
1b
Number: NCT05364073
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
(02) 8037 4100 admin.northshore@genesiscare.comMedical Oncologist
Prof. Nick Pavlakis
BSc MBBS MMed PhD FRACP
Frenchs Forest (Oncology) +1
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.